1. Home
  2. FIG vs VTRS Comparison

FIG vs VTRS Comparison

Compare FIG & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FIG

Figma Inc.

N/A

Current Price

$18.73

Market Cap

10.6B

Sector

Technology

ML Signal

N/A

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$14.99

Market Cap

17.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIG
VTRS
Founded
2012
1961
Country
United States
United States
Employees
1886
30000
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6B
17.5B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
FIG
VTRS
Price
$18.73
$14.99
Analyst Decision
Hold
Buy
Analyst Count
13
4
Target Price
$50.50
$13.50
AVG Volume (30 Days)
14.0M
8.3M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
3.21%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,299,900,000.00
Revenue This Year
$31.18
$4.41
Revenue Next Year
$20.22
$1.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.60
$8.19
52 Week High
$114.29
$16.47

Technical Indicators

Market Signals
Indicator
FIG
VTRS
Relative Strength Index (RSI) 44.90 64.68
Support Level $17.65 $12.90
Resistance Level $21.45 $15.22
Average True Range (ATR) 1.39 0.39
MACD 0.19 0.09
Stochastic Oscillator 44.43 88.03

Price Performance

Historical Comparison
FIG
VTRS

About FIG Figma Inc.

Figma Inc is engaged in transforming ideas into digital products and experiences. The group focuses on the entire software creation lifecycle, enabling it to quickly launch new products on Figma's browser-based platform and reinforcing its belief that design extends well beyond a single step or role. The company adopts an expansive view, as design is more than how something looks, feels, or works. It derives its revenue from sales of subscriptions for access to its platform.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: